Skip to main content
Caplight Logo









Autifony Therapeutics Limited

Autifony Therapeutics Limited

Private
StevenageHealthcare & Life Scienceshttps://autifony.com/

Last Round

Grant

Mar 15, 2017

Total Funding Raised

$43.01M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Autifony Therapeutics Limited is a biotechnology company that develops novel medicines to treat rare genetic CNS disorders by using its ion channel drug discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

Kv3 modulatorsCNS disordersion channel therapeuticsclinical stage biotechsmall molecule drugsdrug discovery platformbiotech licensingFragile X syndromeneurotherapeuticsorphan epilepsyorphan drug designationchannelopathiesschizophreniahearing lossneuronal hyperexcitability

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Autifony Therapeutics Limited Comparables

Compare Autifony Therapeutics Limited with similar companies based on industry and business-model similarity.

Autifony Therapeutics Limited comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kaerus Bioscience
81%
Connecta Therapeutics
80%
Shionogi & Co.
78%

Autifony Therapeutics Limited Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 15, 2017
Series A ExtensionJul 10, 2015
GrantMar 1, 2014
Series A ExtensionJun 4, 2013
Series AAug 22, 2011

Key People

Founding team and executive leadership

Charles Large

Chief Executive Officer

Executive Team

Martin Gunthorpe

CTO, Autifony Therapeutics

Executive Team

Autifony Therapeutics Limited Investors

Notable investors and investment history

Autifony Therapeutics Limited investors
InvestorRounds
SV Health InvestorsSeries A Extension, Series A
Innovate UKGrant
Imperial InnovationsSeries A
Medical Research CouncilGrant
UCL BusinessSeries A Extension
Pfizer VenturesSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 22, 2026

    Monthly visitors grew 332% MoM, reaching 2.3K.

  • Apr 17, 2026

    Monthly visitors increased 30% MoM.

Autifony Therapeutics Limited Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Autifony Therapeutics Limited Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Autifony Therapeutics Limited's valuation, stock price, and market status.

Firmographic Details

HeadquartersStevenage
Employee Range31
Year Founded2011
Last FundingMar 15, 2017

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?